title: Antibiotic prophylaxis for cardiothoracic operations. Meta-analysis of thirty years of clinical trials.
abstract: Antistaphylococcal penicillins and first-generation cephalosporins have traditionally been the prophylactic antibiotics of choice for patients undergoing cardiothoracic operations. Recently published studies have claimed improved outcomes with respect to postoperative wound infection when second-generation cephalosporins were used for prophylaxis. The purpose of this study was to critically review the infectious outcomes of prospective, randomized, and controlled studies of cardiothoracic surgery prophylaxis by means of meta-analytic techniques. For each of 28 studies meeting the meta-analysis entry criteria, odds ratios with 95% confidence intervals were calculated to compare the prophylactic efficacy of the antibiotic regimens. Odds ratios were then pooled, and a summary odds ratio was calculated for each pairing of antibiotic treatments. Placebo-controlled trials of cardiothoracic prophylaxis demonstrated a consistent benefit to the administration of antibiotic prophylaxis, with an approximate fivefold reduction in wound infection rate. The second-generation cephalosporins, cefamandole and cefuroxime, performed better than cefazolin, with an approximate one and one-half-fold reduction in wound infection rate. Administration of prophylaxis beyond 48 hours was not associated with improved infectious outcomes.
authors.affiliation: Department of Anti-Infectives, Bristol-Myers Squibb U.S. Pharmaceutical Division, Princeton, N.J. 08543-4500.
authors.forename: B
authors.initials: B
authors.lastname: Kreter
authors.forename: M
authors.initials: M
authors.lastname: Woods
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D006348:Cardiac Surgical Procedures; D002435:Cefamandole / Q000031:analogs & derivatives / Q000627:therapeutic use; D002437:Cefazolin / Q000627:therapeutic use; D002443:Ceftriaxone / Q000627:therapeutic use; D002444:Cefuroxime / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D002512:Cephalothin / Q000627:therapeutic use; D002515:Cephradine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D016239:MEDLINE; D015201:Meta-Analysis as Topic; D010406:Penicillins / Q000627:therapeutic use; D011184:Postoperative Period; D011292:Premedication; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D013530:Surgical Wound Infection / Q000517:prevention & control*; D013903:Thoracic Surgery
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D010406:Penicillins; D002435:Cefamandole; D002443:Ceftriaxone; C012653:ceforanide; D002515:Cephradine; D002437:Cefazolin; D002444:Cefuroxime; D002512:Cephalothin